Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ: NMRA )

12.33 +0.08 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 232,481
Open 12.24
Bid (Size) 11.00 (1)
Ask (Size) 12.50 (2)
Prev. Close 12.25
Today's Range 11.87 - 12.41
52wk Range 9.350 - 17.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Shares of Salesforce, Inc. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! 
Via InvestorPlace

Performance

YTD
-24.12%
-24.12%
1 Month
+12.91%
+12.91%
3 Month
-24.12%
-24.12%
6 Month
-24.12%
-24.12%
1 Year
-24.12%
-24.12%

More News

Read More
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Neumora Therapeutics's Future
Via Benzinga
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Specialty Asian Grocer Maison Solutions Opens For Trading
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
Jabil, Chico's FAS And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of Neumora Therapeutics Slumped This Week
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
SoftBank-Owned Arm Jumps 20% In Market Debut
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.